Company: DVAX
Filing Date: 2025-04-03
Form Type: PREC14A
Source: 0000930413-25-001153
Chunk: 42

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-03
Form: PREC14A
Chunk 42
---
Our Board does not have a standing risk management committee but rather administers this oversight function
directly through our Board as a whole as well as through our standing committees. In particular, our Board is responsible for
monitoring and assessing strategic risk exposure generally. Our Audit Committee has the responsibility to oversee our major financial
risk exposures and the steps our management has taken to monitor and control these exposures as well as oversight of our enterprise
risk management program. Our Audit Committee also monitors compliance with legal and regulatory requirements, including cybersecurity
and healthcare regulations and industry standards, oversees our guidelines and policies with respect to risks relating to data
privacy, technology and information security, oversees the performance of our internal audit function and approves or disapproves
any related-persons transactions. Our Nominating and Corporate Governance Committee monitors the effectiveness of our corporate
governance guidelines, oversees our ESG and sustainability initiatives including compliance with applicable rules, and manages
the process for annual director self-assessment and evaluation of the Board. Our Compensation Committee assesses and monitors
whether any of our compensation policies and programs has the potential to encourage excessive risk-taking.

| 29 |

COMMITTEES OF THE BOARD OF DIRECTORS

Our Board has three standing committees: an Audit Committee,
a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership and meeting
information for fiscal year 2024 for each of the

Board committees:

| Name                     |     |   Audit |     | Compensation |     | Nominating and 
      Corporate 
     Governance |
| Scott Myers(2)           |     |         |     |              |     |                |
| Francis R. Cano, Ph.D.   |     |         |     |              |     |         Member |
| Julie Eastland(1)        |     |  Chair* |     |              |     |                |
| Emilio Emini, Ph.D.      |     |         |     |              |     |                |
| Daniel L. Kisner, M.D.   |     |         |     |       Member |     |          Chair |
| Brent MacGregor          |     |         |     |              |     |         Member |
| Peter R. Paradiso, Ph.D. |     |         |     |       Member |     |                |
| Peggy V. Phillips(1)     |     |  Member |     |        Chair |     |                |
| Lauren Silvernail(2)     |